Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1)
These medicines may not be suitable for people with: History of medullary thyroid cancer Multiple Endocrine Neoplasia type 2 (MEN2) Pregnancy Severe gastrointestinal disorders Certain pancreatic conditions Your doctor will assess whether these medications are appropriate for you
Plateau Length: Your weight has remained completely unchanged for a continuous period exceeding three months consistently
For tirzepatide, 2.5 mg weekly
The new daily oral Wegovy option is a game changer, says Chatham
These drugs offer substantial potential health benefits, but the combination of intense demand, new uses, and high prices for these treatments is likely to place tremendous pressure on Medicare spending, Part D plan costs, and premiums for Part D coverage.